169 related articles for article (PubMed ID: 38329487)
1. Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study.
Zhao L; Yang J; Chen M; Xiang X; Ma H; Niu T; Gong Y; Chen X; Liu J; Wu Y
Ann Hematol; 2024 Apr; 103(4):1197-1209. PubMed ID: 38329487
[TBL] [Abstract][Full Text] [Related]
2. [Effect of venetoclax plus chemotherapy on treatment-naive acute myeloid leukemia patients with moderate to poor cytogenetic profiles and the combination's influence on the expression of proteins of the anti-apoptoic family].
Zhonghua Zhong Liu Za Zhi; 2024 Feb; 46(2):161-167. PubMed ID: 38418191
[No Abstract] [Full Text] [Related]
3. The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study.
Xin F; Yu YH; Shen XL; Zhang GX
Hematology; 2024 Dec; 29(1):2350319. PubMed ID: 38748459
[TBL] [Abstract][Full Text] [Related]
4. Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy.
Weng G; Huang J; An N; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; He X; Jin H; Liu Q; Du X
Cancer Med; 2024 Jan; 13(2):e6885. PubMed ID: 38334500
[TBL] [Abstract][Full Text] [Related]
5. [Short-term Effect of Venetoclax Combined with Azacitidine and "7+3" Regimen in the Treatment of Newly Diagnosed Elder Patients with Acute Myeloid Leukemia].
Liu XX; Wen XL; Li RQ; Zhang XL; Zhang TB; Dong CX; Wang MF; Zhang JH; Yang LH; Zhang RJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):96-103. PubMed ID: 38387906
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
Abaza Y; Winer ES; Murthy GSG; Shallis RM; Matthews AH; Badar T; Geramita EM; Kota VK; Swaroop A; Doukas P; Bradshaw D; Helenowski IB; Liu Y; Zhang H; Im A; Litzow MR; Perl AE; Atallah E; Altman JK
Am J Hematol; 2024 Apr; 99(4):606-614. PubMed ID: 38342997
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of the Efficacy and Prognosis Factors of Acute Myeloid Leukemia with a Combination Therapy of Venetoclax].
Ren CC; Zhang WW; Wu TK; Liu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):104-111. PubMed ID: 38387907
[TBL] [Abstract][Full Text] [Related]
8. Limited Efficacy of Venetoclax Combination Regimens in Acute Myeloid Leukemia with Extramedullary Relapse.
Bae S; Sa S; Park S; Cho BS; Kim HJ
Acta Haematol; 2024; 147(3):352-359. PubMed ID: 37751714
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and Survival of Venetoclax Based Regimen in the Treatment of Acute Myeloid Leukemia].
Kong FC; Qi L; Huang WF; Yu M; Zhou YL; Ji DX; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1676-1683. PubMed ID: 38071045
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
Fleischmann M; Scholl S; Frietsch JJ; Hilgendorf I; Schrenk K; Hammersen J; Prims F; Thiede C; Hochhaus A; Schnetzke U
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3191-3202. PubMed ID: 35099591
[TBL] [Abstract][Full Text] [Related]
11. Ten-day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score-matched analysis.
Maiti A; DiNardo CD; Qiao W; Kadia TM; Jabbour EJ; Rausch CR; Daver NG; Short NJ; Borthakur G; Pemmaraju N; Yilmaz M; Alvarado Y; Montalbano KS; Wade A; Maduike RE; Guerrero JA; Vaughan K; Bivins CA; Pierce S; Ning J; Ravandi F; Kantarjian HM; Konopleva MY
Cancer; 2021 Nov; 127(22):4213-4220. PubMed ID: 34343352
[TBL] [Abstract][Full Text] [Related]
12. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
[No Abstract] [Full Text] [Related]
13. Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients.
Garciaz S; Hospital MA; Alary AS; Saillard C; Hicheri Y; Mohty B; Rey J; D'Incan E; Charbonnier A; Villetard F; Maisano V; Lombardi L; Ittel A; Mozziconacci MJ; Gelsi-Boyer V; Vey N
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454930
[TBL] [Abstract][Full Text] [Related]
14. Monocytic Differentiation of Human Acute Myeloid Leukemia Cells: A Proteomic and Phosphoproteomic Comparison of FAB-M4/M5 Patients with and without Nucleophosmin 1 Mutations.
Selheim F; Aasebø E; Reikvam H; Bruserud Ø; Hernandez-Valladares M
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791118
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and Safety of Venetoclax-Based Induction Therapy in Acute Myeloid Leukemia].
Feng J; Yuan RF; Tang HL; Bai QX; Yang L; Dong HJ; Liang R; Zhang T; Gu HT; Gao GX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Auguest; 31(4):960-966. PubMed ID: 37551462
[TBL] [Abstract][Full Text] [Related]
16. Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia.
Cui J; Chen X; Li C; Yan Q; Yuan G
Hematology; 2024 Dec; 29(1):2293512. PubMed ID: 38095287
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study.
Mustafa Ali MK; Corley EM; Alharthy H; Kline KAF; Law JY; Lee ST; Niyongere S; Duong VH; Emadi A; Baer MR
Front Oncol; 2022; 12():858202. PubMed ID: 35433414
[TBL] [Abstract][Full Text] [Related]
18. Selective eradication of venetoclax-resistant monocytic acute myeloid leukemia with iron oxide nanozymes.
Zhang S; Lou S; Bian W; Liu J; Wang R; Wang Y; Zhao Y; Zou X; Jin D; Liang Y; Sun J; Liu L
Biochem Biophys Res Commun; 2024 May; 719():150117. PubMed ID: 38761635
[TBL] [Abstract][Full Text] [Related]
19. Assessment of monocytic component in acute myelomonocytic and monocytic/monoblastic leukemias by a chemiluminescent assay.
da Fonseca LM; Brunetti IL; Campa A; Catalani LH; Calado RT; Falcão RP
Hematol J; 2003; 4(1):26-30. PubMed ID: 12692517
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD
Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
